All About Pharmaceuticals

AI applications for healthcare are becoming more common for white-collar automation and diagnostics . However, medical robotics is an area that may be marginally underdeveloped. This is likely because of regulations concerning automated surgery. In this article, I cover how AI software is finding its way into medical robotics now and how it might in the future with more investment and when the density of AI talent at medical robotics companies increases. Specifically, we explore: AI for Medical Robotics – What’s Possible, and What’s Being Used by healthcare clients right now. We found little to no case studies showing a health network or hospital’s success with AI-based medical robotics. The State of AI at Medical Robotics Vendors – the AI talent at medical robotics companies and a discussion of how to vet a vendor on whether or not its software is truly leveraging AI We begin our exploration of AI applications for medical robotics with an overview of the po

To improve transparency and encourage the development and submission of abbreviated new drug applications (ANDAs) for drugs with limited competition, FDA is publishing a list, consistent with the methodology described below, of approved new drug application (NDA) drug products that are off-patent and off-exclusivity, and for which the FDA has not approved an ANDA referencing that NDA drug product. Part I of the list identifies those drug products for which FDA could immediately accept an ANDA without prior discussion. Part II identifies drug products for which ANDA development or approval may raise potential legal, regulatory, or scientific issues that should be addressed with the Agency prior to considering submission of an ANDA. The Appendix identifies NDA drug products that were removed from Part I or Part II of the list because one or more ANDAs referencing such NDA drug products have been approved since the previous list publication. Sponsors wishing to pursue approval of AN